Evidence map›Paper›PMID 37760177›Full record

ArticleBioengineering (Basel, Switzerland)2023

Isolation and Biological Evaluation of Alfa-Mangostin as Potential Therapeutic Agents against Liver Fibrosis.

Yi-Jen Liao, Chun-Ya Lee, Yuh-Ching Twu, Fat-Moon Suk, Tzu-Chieh Lai, Ya-Ching Chang, Yi-Cheng Lai, Jing-Wei Yuan, Hong-Ming Jhuang, Huei-Ruei Jian and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Molecular medicine reports · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Yi-Jen LiaoSchool of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-9836-1503
Chun-Ya LeeSchool of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Yuh-Ching TwuDepartment of Biotechnology and Laboratory Science in Medicine, School of Biomedical Science and Engineering, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.ORCID 0000-0003-0327-0738
Fat-Moon SukDivision of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan.ORCID 0000-0001-9218-6532
Tzu-Chieh LaiDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.
Ya-Ching ChangDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.
Yi-Cheng LaiDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.
Jing-Wei YuanDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.
Hong-Ming JhuangDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.
Huei-Ruei JianDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.
Li-Chia HuangDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.
Kuang-Po ChenDepartment of Chemistry, Chinese Culture University, Taipei 111, Taiwan.
Ming-Hua HsuDepartment of Chemistry, National Changhua University of Education, Changhua 500, Taiwan.ORCID 0000-0002-8711-8815
National Changhua University of Education · TWTaipei Medical University · TWChinese Culture University · TWNational Yang Ming Chiao Tung University · TWWan Fang Hospital · TW

Funding

National Science and Technology Council (NSTC), Republic of China MOST 110-2113-M-018-006National Science and Technology Council (NSTC), Republic of China MOST 111-2320-B-038-058
6 · The paper itself

Abstract

The increased proliferation and activation of hepatic stellate cells (HSCs) are associated with liver fibrosis development. To date, there are no FDA-approved drugs for the treatment of liver cirrhosis. Augmentation of HSCs apoptosis is one of the resolutions for liver fibrosis. In this study, we extracted α-mangostin (1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one) from the fruit waste components of mangosteen pericarp. The isolated α-mangostin structure was determined and characterized with nuclear magnetic resonance (NMR) and high-resolution mass spectrometry (HRMS) and compared with those known compounds. The intracellular signaling pathway activities of α-mangostin on Transforming growth factors-beta 1 (TGF-β1) or Platelet-derived growth factor subunit B (PDGF-BB) induced HSCs activation and were analyzed via Western blot and Real-time Quantitative Polymerase Chain Reaction (Q-PCR). α-Mangostin-induced mitochondrial dysfunction and apoptosis in HSCs were measured by seahorse assay and caspase-dependent cleavage. The in vivo anti-fibrotic effect of α-mangostin was assessed by carbon tetrachloride (CCl

Indexed as

alfa-mangostinliver fibrosismangostin

Identifiers

PMID37760177
PMCPMC10526009
OpenAlexW4386601122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.